home / stock / lctx / lctx news

LCTX News and Press, BioTime Inc. From 11/09/23

Stock Information
Company Name: BioTime Inc.
Stock Symbol: LCTX
Market: NYSE
Website: lineagecell.com
Menu
LCTX LCTX Quote LCTX Short LCTX News LCTX Articles LCTX Message Board
Get LCTX Alerts

News, Short Squeeze, Breakout and More Instantly...
LCTX - Lineage Cell Therapeutics GAAP EPS of -$0.04 in-line, revenue of $1.25M misses by $1.33M

2023-11-09 16:05:08 ET More on Lineage Cell Therapeutics A Second Look At Lineage Cell Therapeutics Lineage Cell Therapeutics Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Lineage Cell Therapeutics Historical earnings data for Lineage Cell T...
LCTX - Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Enrollment Continues in Phase 2a Clinical Study of RG6501 (OpRegen ® ) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Under Management of Genentech, a Member of the Roche Group Additional RG6501 (OpRegen ® ) Data Presented at...

LCTX - Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 9, 2023, followin...

LCTX - RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting

Company Also Will Present at “Mapping the Future of Geographic Atrophy” Session at Eyecelerator@AAO 2023 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs,...
LCTX - Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,746,324, entitled “...

LCTX - RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the results of imaging analyses demonstrating rapid improvement in outer retinal structure from patients enro...

LCTX - A Second Look At Lineage Cell Therapeutics

2023-10-04 09:38:04 ET Summary Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on developing cell therapies for degenerative diseases. The shares trade for just over a buck apiece. Five analyst firms have reissued Buy/Outperform ratings on the stock, wi...
LCTX - Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the Cantor Fitzgerald 2023 Globa...

LCTX - RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the results of imaging analyses demonstrating evidence of rapid improvement in outer retinal structure from a...

LCTX - Lineage to Present at 2023 International Spinal Research Trust Network Meeting

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Gary S. Hogge, D.V.M., M.S., Ph.D., Lineage’s Senior Vice President, Clinical & Medical Affairs, w...
Previous 10 Next 10